A Post Market Study to Assess the Spinal Modulation Dorsal Root Ganglion Stimulator System in Chronic Post Surgical Pain

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-30

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

20-SMI-2013 is a post market, observational, questionnaire based study to assess the effectiveness of the commercially available Axium neurostimulator in the management of chronic post surgical pain

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients

NCT00290238

Low Back Pain

TERMINATED PHASE4

Electromyographic Response to TsDcs in CNSLBP

NCT06712992

Low Back Pain

ACTIVE_NOT_RECRUITING NA

Impact of DuoTherm on Opioid Use and Low Back Pain

NCT04491175

Opioid Use Low Back Pain

COMPLETED NA

Effects of a Mechanical Needle Stimulation Pad on Chronic Low Back Pain

NCT02487368

Chronic Low Back Pain Recurrent Low Back Pain

COMPLETED NA

Evaluation of Endogenous Pain Modulation Mechanisms With Transcutaneous Electrical Nerve Stimulation

NCT04236570

Chronic Pain

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Post Surgical Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Axium DRG Neurostimulator

All eligible subjects recruited and treated with the Axium Neurostimulator

Axium DRG Neurostimulator

Intervention Type DEVICE

Implantation with Axium DRG Neurostimulator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Axium DRG Neurostimulator

Implantation with Axium DRG Neurostimulator

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is at least 18 years old
2. Subject is able and willing to comply with the follow-up schedule and protocol
3. Chronic post surgical pain for at least 6 months
4. Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain
5. Minimum baseline pain rating of 60 mm on the Visual Analog Scale in the primary region of pain
6. Subject is able to provide written informed consent
7. Pain medication dosage has been stable for at least 30 days
8. Patient has been included for implantation according to standard criteria from the Dutch Neuromodulation Society

Exclusion Criteria

1. Female subject of childbearing potential is pregnant/nursing, plans to become pregnant or is unwilling to use approved birth control
2. Escalating or changing pain condition within the past month as evidenced by investigator examination
3. Subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days
4. Subject has had radiofrequency treatment of an intended target Dorsal Root Ganglion within the past 3 months
5. Subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump
6. Subject is unable to operate the device
7. Subjects with indwelling devices that may pose an increased risk of infection
8. Subjects currently has an active infection
9. Subject has participated in another clinical investigation within 30 days
10. Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation
11. Subject has been diagnosed with cancer in the past 2 years.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No